Alvotech Revenue Growth Rates (ALVO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Alvotech  (NASDAQ: ALVO)
 

ALVO's Revenue Growth by Quarter and Year

Alvotech's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALVO Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 588.90
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 588.90





ALVO Revenue fourth quarter 2025 Y/Y Growth Comment
Alvotech showed record Revenue rise in the fourth quarter 2025 with 19.7% from the fourth quarter 2025 2024, to $ 588.90 millions.
This represents worst decline in recent Company history.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 37 other companies have achieved higher Revenue growth. While Alvotech' s Revenue growth of 19.7% ranks overall at the positon no. 917 in the fourth quarter 2025.


ALVO Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 19.7 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   19.7 % - - -

Financial Statements
Alvotech's fourth quarter 2025 Revenue $ 588.90 millions ALVO's Income Statement
Alvotech's fourth quarter 2024 Revenue $ 491.98 millions Quarterly ALVO's Income Statement


ALVO Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   19.7 % - - -


Back to ALVO Growth rate Comparisons >> Back to ALVO Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #38
Healthcare Sector #209
Overall #917

Revenue Y/Y Growth Statistics
High Average Low
19.7 % 19.7 % 19.7 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #38
Healthcare Sector #209
Overall #917
Revenue Y/Y Growth Statistics
High Average Low
19.7 % 19.7 % 19.7 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Alvotech's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALVO's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ALVO's IV. Quarter Q/Q Revenue Comment


Alvotech's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 588.90 $ 491.98 $ 140.13 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 19.7 % 251.08 % 29.92 % - -
Year on Year Revenue Growth Overall Ranking # 876 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 19.7 % 251.08 % 29.92 % - -
Seq. Revenue Growth (TTM) Overall Ranking # 894 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With 19.7% annual Revenue growth, Alvotech would report a record annual Revenue increase if the fiscal year would end on Dec 31 2025.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 876.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 182
Overall # 876

Revenue TTM Y/Y Growth Statistics
High Average Low
19.7 %
 19.7 %
19.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 183
S&P 500 # 894
Cumulative Revenue growth Comment
With 19.7% annual Revenue growth, Alvotech would report a record annual Revenue increase if the fiscal year would end on Dec 31 2025.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 876.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 182
Overall # 876

Revenue TTM Y/Y Growth Statistics
High Average Low
19.7 %
19.7 %
19.7 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 183
S&P 500 # 894




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALVO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Clearpoint Neuro Inc 33.96%$ 33.960 millions
Therapeuticsmd Inc 33.88%$ 33.883 millions
Apyx Medical Corp33.65%$ 33.647 millions
Gyre Therapeutics Inc 33.45%$ 33.449 millions
Harrow Inc 33.31%$ 33.309 millions
Delcath Systems Inc 33.28%$ 33.282 millions
Beone Medicines Ltd 32.84%$ 32.837 millions
Veracyte Inc 32.81%$ 32.815 millions
Transmedics Group Inc 32.18%$ 32.181 millions
Medpace Holdings Inc 32.03%$ 32.028 millions
Quipt Home Medical Corp 31.96%$ 31.956 millions
Immutep Limited31.80%$ 31.801 millions
Medicure Inc 31.72%$ 31.716 millions
Insulet Corporation31.16%$ 31.163 millions
Exagen Inc 31.08%$ 31.083 millions
Cumberland Pharmaceuticals Inc 31.08%$ 31.077 millions
Ani Pharmaceuticals Inc29.64%$ 29.640 millions
Vistagen Therapeutics Inc 29.49%$ 29.487 millions
Stereotaxis Inc 29.25%$ 29.254 millions
Talkspace Inc 29.00%$ 29.003 millions
Aurinia Pharmaceuticals Inc 28.81%$ 28.809 millions
Hims and Hers Health Inc 28.64%$ 28.636 millions
Neurocrine Biosciences Inc 28.33%$ 28.326 millions
Incyte Corporation27.84%$ 27.839 millions
Puma Biotechnology Inc 27.72%$ 27.720 millions
Armata Pharmaceuticals Inc 27.61%$ 27.611 millions
Agenus Inc27.45%$ 27.451 millions
Brainsway Ltd 27.33%$ 27.328 millions
Irhythm Holdings Inc 27.25%$ 27.254 millions
Neuraxis Inc 27.19%$ 27.190 millions


About Alvotech Revenue Growth Rates (ALVO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Alvotech (CIK 1898416).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001898416-26-000004
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Alvotech’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.